Pfizer Sets Sights On Becoming Top Five Biologics Player By 2010
Executive Summary
Pfizer is emphasizing a diversified approach, focusing on both small molecules and biotech products, as it attempts to regain investor confidence in the company's growth potential
You may also be interested in...
Pfizer ups BIO ante
Pfizer CEO Jeffrey Kindler is elected to the Biotechnology Industry Organization's Board of Directors, replacing Pfizer VP-Corporate Policy and Strategic Management Fred Telling. Retiring from Pfizer this year, Telling has served on the BIO board for eleven years. Pfizer has been working to expand its presence in biotech in recent years (1"The Pink Sheet" Feb. 20, 2006, p. 19)...
Pfizer ups BIO ante
Pfizer CEO Jeffrey Kindler is elected to the Biotechnology Industry Organization's Board of Directors, replacing Pfizer VP-Corporate Policy and Strategic Management Fred Telling. Retiring from Pfizer this year, Telling has served on the BIO board for eleven years. Pfizer has been working to expand its presence in biotech in recent years (1"The Pink Sheet" Feb. 20, 2006, p. 19)...
Pfizer’s Lipitor Extension Shot Down By Failure Of Torcetrapib Silver Bullet
Pfizer will likely have to look to a constellation of smaller products, rather than a single large product, to replace Lipitor after the termination of the torcetrapib development program